The top story in November discussed the impacts of CMS cuts on patient access, with an interview with an expert on the subject. FDA news also made headlines during the month. The CMS finalized cuts to the 2025 physician fee schedule, prompting concerns from the American Academy of Dermatology. The FDA approved Emrosi for rosacea and Bimzelx for hidradenitis suppurativa in adults. Other articles highlighted the importance of using correct pronouns for transgender patients, the approval of a wound dressing with lidocaine, and skincare regimens for photoaging. Additionally, studies showed the benefits of poly-L-lactic acid injections and the link between hidradenitis suppurativa and adverse maternal outcomes.
Source link
Exclusive interview on 2025 physician fee schedule cuts leads November dermatology news
